A recent epidemic of Zika virus in the Americas, affecting well over a million people, caused substantial mortality and morbidity, including Guillain-Barre syndrome, microcephaly and other fetal developmental defects 1,2 . Preventive and therapeutic measures that specifically target the virus are not readily available. The transmission of Zika virus is predominantly mosquito-borne, and Aedes aegypti mosquitoes serve as a key vector for Zika virus 3 . Here, to identify salivary factors that modulate mosquito-borne Zika virus infection, we focused on antigenic proteins in mice that were repeatedly bitten by mosquitoes and developed antibodies against salivary proteins. Using a yeast surface display screen, we identified five antigenic A. aegypti salivary proteins in mice. Antiserum against one of these five proteins-A. aegypti bacteria-responsive protein 1 (AgBR1)-suppressed early inflammatory responses in the skin of mice bitten by Zika-virus-infected mosquitoes. AgBR1 antiserum also partially protected mice from lethal mosquito-borne-but not needle-injected-Zika virus infection. These data suggest that AgBR1 is a target for the prevention of mosquito-transmitted Zika virus infection.
Mosquitoes inject numerous salivary proteins into the skin of a host during blood feeding 4 and these molecules are capable of modulating various host responses 5, 6 . Mosquito saliva enhances the transmission and pathogenicity of specific arboviruses 7, 8 . Although mosquito saliva can increase arboviral infectivity, only a limited number of specific salivary proteins that influence these processes have been characterized. The biogenic amine-binding D7 protein partially inhibits dengue infection, whereas saliva serine protease CLIPA3 enhances the dissemination of dengue virus into the mammalian host 9, 10 . In addition, salivary factor LTRIN from Aedes aegypti facilitates the transmission of Zika virus by inhibiting NFκB signalling during infection 11 . Despite these efforts, much remains to be discovered about how specific salivary factors facilitate mosquito-borne virus infection and whether targeting these proteins can prevent or delay infection.
To identify salivary factors that modulate mosquito-borne Zika virus infection, we focused on antigenic proteins in a vertebrate host repeatedly bitten by A. aegypti mosquitoes. Although previous studies have identified several antigenic proteins using SDS-PAGE and proteomics 12 , it is difficult for these methods to detect proteins with low abundance and antigenicity 13 . We therefore employed a yeast surface display screen here, which can identify uncommon proteins by iterative rounds of magnetic-activated cell sorting 14 .
An A. aegypti salivary gland yeast surface display library was generated and probed with IgG from mice repeatedly bitten by A. aegypti ( Supplementary Fig. 1 ). Individual yeast cell clones expressing salivary proteins that were identified using these sera ( Fig. 1a,b ) were enriched and isolated, and the recombinant plasmids were recovered and sequenced. Five unique mosquito genes were found, including previously identified mosquito proteins and some with unknown function (Supplementary Table 1 ). Among the five identified proteins, A. aegypti bacteria-responsive protein 1 (AgBR1), which we confirmed by immunoblotting, was recognized by the serum of mice bitten by mosquitoes ( Supplementary Fig. 2 ) and had substantial homology (identities = 27%, positives = 43%) with murine chitinase 3 like-1 protein ( Supplementary Fig. 3 ), a protein with putative functions in host defence, inflammation and repair 15 . AgBR1 is also known to be upregulated in the salivary glands of mosquitoes after blood feeding 16 . However, the function of AgBR1 in the vertebrate host remains unknown. We therefore examined whether AgBR1 stimulates inflammatory responses in vitro. Murine splenocytes stimulated with recombinant AgBR1 (Fig. 1c,d ) that was produced in S2 cells (5 µg ml −1 ) demonstrated significantly higher levels of Il6 expression compared with controls ( Fig. 1e ). As increased vascular permeability contributes to flavivirus pathogenicity 17 and IL6 is associated with these processes 18 , we next examined whether AgBR1 influences Zika virus infection in vivo. Given that previous studies demonstrated that approximately half of the protein in salivary glands is discharged during a blood meal 19, 20 , the concentration of AgBR1 in mosquito saliva can be estimated to be between 1.6 and 8.2 µM (Supplementary Fig. 4 and Supplementary  Table 2 ). We thus injected AG129 mice with Zika virus and AgBR1 (5.1 µM; 10 µg AgBR1 in a total volume of 40 µl). At day 3 postinfection, significantly higher viraemia levels were observed in the group of mice inoculated with Zika virus in conjunction with AgBR1 compared with mice challenged with Zika virus alone ( Fig. 1f ). In addition, AgBR1 protein significantly impaired the survival of Zikavirus-infected mice (Fig. 1g ). These results demonstrate that AgBR1 can exacerbate Zika virus infection and disease in vivo.
Next, we examined whether blocking AgBR1 in vivo affects mosquito-borne Zika virus infection. Rabbit antiserum against recombinant AgBR1 reacted strongly, and specifically, with the recombinant protein and recognized native AgBR1 in the mosquito salivarygland extracts ( Fig. 2a ). We treated mice with AgBR1 antiserum to determine whether inhibiting this protein modulates pathogenesis during A. aegypti-borne Zika virus infection. AG129 mice were administered with AgBR1 or control antiserum and were bitten by two Zika-virus-infected A. aegypti mosquitoes 24 h later (Fig. 2b) . The levels of Zika virus in the salivary glands were similar for all mosquitoes, suggesting that the mice were exposed to comparable levels of the virus (Fig. 2c ). We then determined whether AgBR1 antiserum altered Zika virus infection in mice. AgBR1 antiserum significantly reduced the level of Zika virus in mice over the course of viral infection ( Fig. 2d ) and provided partial protection against Zika-virus-induced pathogenesis and death ( Fig. 2e ). We also found that the partial protective effect of AgBR1 antibodies was specific for mosquito-borne-and not needle-injected-Zika virus infection in mice ( Supplementary Fig. 5 ). We also assessed whether active immunization with AgBR1 could be effective in providing protection. AG129 mice were immunized three times with 10 µg AgBR1 in either complete or incomplete Freund's adjuvant. After the final boost, high titres of AgBR1 antibodies were detected ( Supplementary Fig. 6a ). Actively immunized mice displayed significantly reduced viraemia at day 5 and showed significantly better survival from mosquito-borne Zika virus infection than control mice ( Supplementary Fig. 6b ,c), which suggests that, similar to passive immunization, active immunization with AgBR1 delays the appearance of clinical signs and death in the animals. Here, we used AG129 mice that lack both type I and II inteferon receptors but can elicit B-and T-cell responses 21, 22 . As type I interferon signalling can contribute to optimal antibody responses 23 , it is possible that further efforts using alternative adjuvants, protein concentrations or different animal models could enhance the effect of active immunization. Overall, these results indicate that immunization with AgBR1 partially influences mosquito-transmitted Zika virus infection.
To determine whether the effects observed with AgBR1 extended to other proteins identified in our screen, we chose two other proteins, D7Bclu and SP, the expression of which has been identified as being upregulated in salivary glands during flavivirus infection 10 . We generated D7Bclu and SP antisera in a similar fashion to the AgBR1 antiserum and performed passive immunization experi- ments. Neither the D7Bclu nor SP antisera altered the viraemia or protected mice from lethal mosquito-borne Zika virus infection ( Supplementary Fig. 7 ).
To better understand the underlying mechanism of protection of immunization with AgBR1, we examined whether AgBR1 antiserum influenced the early innate immune response at bite sites after mice were exposed to Zika-virus-infected mosquitoes. Histological analysis of the bite site 24 h post-feeding by Zikavirus-infected mosquitoes showed prominent inflammatory cell infiltration (mainly composed of neutrophils) in the dermis of mice administered with naive serum (control), which was less apparent in mice administered with AgBR1 antiserum ( Fig. 3a and Supplementary Table 3 ). Consistent with these findings, histology scores were significantly lower in mice administered with AgBR1 antiserum compared with mice administered with naive serum (Fig. 3b ). Furthermore, imaging mass cytometry showed that the infiltrating cells at the bite site of Zika-virus-infected mosquitoes were mainly Ly6G + and CD11b + cells, thus supporting the observation made under haematoxylin and eosin staining that the infiltrating cells are predominantly composed of neutrophils, monocytes and macrophages, with some minor populations of T and other immune cells ( Fig. 3c ). In addition, in contrast to control animals, the infiltration of Ly6G + and CD11b + cells was reduced in mice administered with AgBR1 antiserum (Fig. 3c ). The alteration of the cell populations infiltrating the bitten skin of mice administered with AgBR1 antiserum indicates that AgBR1 antiserum influenced the number of CD45 + CD11b + Ly6G + neutrophils at the bite site ( Fig. 3d,e ). These results suggest that AgBR1 antiserum suppressed acute inflammation, particularly the neutrophilic response, at the mosquito-bite site.
To examine the direct effect of AgBR1 in the skin, we examined whether CD45 + CD11b + Ly6G + cells are recruited into the intradermally injected skin site. More CD45 + CD11b + Ly6G + cells infiltrated into the AgBR1-injected skin compared with the resting skin, suggesting that AgBR1 can recruit CD45 + CD11b + Ly6G + cells ( Supplementary Fig. 8 ). As a mosquito bite represents a more natural introduction of AgBR1 into the skin, we investigated whether the suppression of AgBR1-gene and AgBR1-protein expression in salivary glands alters the infiltration levels of CD45 + CD11b + Ly6G + cells after a mosquito bite ( Supplementary Fig. 9a,b ). The levels of experiments with similar results. e, Percentage of CD45 + CD11b + Ly6G + cells in the total CD45 + leukocyte cell population at 24 h after Zika-virus-infected mosquito feeding. Each dot represents one mouse. Statistical significance was calculated using a two-way ANOVA test for multiple comparisons. The data are presented as the mean ± s.e.m. n = 7 (resting skin control), 9 (bitten skin control), 11 (AgBR1 antiserum, resting skin and AgBR1 antiserum, bitten skin) biologically independent samples pooled from 2 separate experiments.
Zika virus were similar in the salivary glands of both the dsRNAtreated mosquito groups ( Supplementary Fig. 9c ) and we found that the levels of CD45 + CD11b + Ly6G + cells were significantly increased in mice bitten by control mosquitoes, but not in mice bitten by AgBR1-dsRNA-treated mosquitoes ( Supplementary Fig.  9d ). These results further demonstrate that AgBR1 plays a role in recruiting CD45 + CD11b + Ly6G + cells to the bite site of a Zikavirus-infected mosquito.
To further understand how AgBR1 may influence mosquitoborne Zika infection, we performed RNA sequencing (RNA-seq) on mice tissue collected from the bite site 24 h after Zika-virusinfected-mosquito feeding. We found that of the 986 genes that were differentially expressed between the bite and resting sites in control mice following feedings by Zika-virus-infected mosquitoes, 536 were upregulated ( Fig. 4a and Supplementary Table. 4). A variety of cytokine and chemokine genes, including the neutrophilattracting chemokine Cxcl1, proinflammatory cytokine Il1b and monocytic chemoattractive chemokines Ccl2 and Ccl6, were significantly upregulated at the bite site compared with the resting site. This result was consistent with a previous report describing a detrimental role for inflammatory neutrophils that express IL-1β in the induction of cutaneous inflammatory responses at the bite site 7, 24 . Gene set enrichment analysis (GSEA) also revealed that inflammatory responses and cytokine signalling, which are mediated by host immune cells, were highly enriched in bitten skin, supporting our histological findings ( Fig. 4b and Supplementary Table 5 ).
Next, we sought to evaluate the impact of AgBR1 antiserum on the inflammatory responses induced by the bites of Zika-virusinfected mosquitoes. To this end, we focused on genes that were upregulated at the bite site and identified 18 genes, including Il1b, Cxcl1 and Ccl2, that were attenuated in the mice inoculated with AgBR1 antiserum (Fig. 4a,c) . The reduction in Il1b expression was also confirmed by quantitative RT-PCR (qRT-PCR; Fig. 4d ). In addition, we examined the Il6 expression levels in each group because AgBR1 stimulates Il6 expression in vitro. Il6 was initially not included in the differential gene expression analysis due to the low expression levels in control skin. Il6 expression levels were nonetheless significantly suppressed in AgBR1-antiserum-treated mice compared with control mice, which was consistent with the in vitro data (Fig. 4d ). We also found that direct inoculation of AgBR1 into the skin significantly induces Il1b and Il6 expression ( Supplementary Fig. 10 ).
Arboviral infection triggers the recruitment of peripheral neutrophils and monocytes to the site of infection 7, 25 , and previous studies showed that neutrophils are important targets of flaviviruses in vivo and that the infiltration of neutrophils contribute to the initial flavivirus infection and dissemination 7, 26, 27 . Here, we show that AgBR1 induces neutrophil recruitment at the bite site and blocking 
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Enrichment score this effect suppresses the early host response ( Figs. 3 and 4) . These data suggest that targeting AgBR1 blocks the early host responses caused by the bite of Zika-virus-infected mosquitoes, leading to the suppression of viral dissemination and protection against lethal Zika virus infection.
To mimic mosquito salivation, we performed intradermal injections of AgBR1. A recent study demonstrated that infection with mosquito-borne Zika virus alters tissue tropism and replication kinetics of the virus, compared with needle inoculation 28 . In addition, the results using needle injection of recombinant AgBR1 protein are modest compared with those using AgBR1 antiserum or in the context of mosquito bites (Figs. 1-2 and Supplementary Figs.  6,8,9,10) . These results implied the possibility that AgBR1 may enhance its functions in cooperation with other molecules in saliva, as mosquito saliva contains many components. Further elucidation of the synergistic effect of AgBR1 with other salivary factors or the role that AgBR1 plays during natural mosquito feedings will therefore pave the way for understanding how AgBR1 influences the vertebrate host at the local site and for the development of novel vaccines against Zika virus that target antigens produced by the arthropod vector.
There is an urgent need for the development of a vaccine against the Zika virus. Conventional human vaccines against infectious diseases are based on components of specific pathogens 21 , which often lead to the emergence of escape mutants 29 . On the other hand, given that the approach of targeting an arthropod protein does not exert a direct effect on the vectors themselves, the emergence of resistant mosquitoes is unlikely to occur. In addition, an arthropod-based target may enhance the efficacy of future Zika-virus-specific vaccines that are now in development. This approach also offers a functional paradigm for developing vaccines against other flaviviruses and arthropod-borne pathogens of medical importance. Moreover, it is probable that there are functional redundancies in facilitating infection with multiple pathogens and this approach could lead to the generation of vaccines that are effective against diverse viruses transmitted by A. aegypti.
Methods
Ethics statement. All experiments were performed in accordance with the guidelines from the Guide for the Care and Use of Laboratory Animals of the NIH. The animal experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the Yale University School of Medicine (assurance no. A3230-01). All infection experiments were performed in a biosafety level 2 animal facility, according to Yale University regulations. Every effort was made to minimize murine pain and distress. The mice were anaesthetized with ketaminexylazine for mosquito infection experiments and euthanized as suggested by the Yale IACUC.
Viruses and cell lines. Vero cells (ATCC) were maintained in DMEM containing 10% FBS and antibiotics at 37 °C with 5% CO 2 . Aedes albopictus C6/36 cells were grown in DMEM media supplemented with 10% FBS, 1% tryptose phosphate and antibiotics at 30 °C with 5% CO 2 . Drosophila S2 cells (ATCC) were passaged in Schneider's Drosophila media with 10% FBS at 28 °C. A Mexican strain of Zika virus (accession no. KX446950), MEX2-81, was propagated in C6/36 insect cells.
Mosquitoes and animals.
A. aegypti (Ho Chi Minh strain, obtained from the J. Powell laboratory at Yale) mosquitoes were maintained on 10% sucrose feeders inside a 12" × 12" × 12" metal mesh cage (BioQuip, 1450B) at 28 °C and ~80% humidity. Egg masses were generated via blood-meal feeding on naive mice. All mosquitoes were housed in a warm chamber in a space approved for Biosafety Level 2 and Arthropod Containment Level 3 research. Four-to six-week-old mixed gender Ifnαr1 −/− Ifnγr −/− mice (AG129-SV129 background) were used in the Zika virus infection studies 30 . The mice were randomly chosen for experimental groups. For isolating splenocytes, five-week-old male C57BL/6 mice were purchased from Jackson Laboratory. All mice were kept in a pathogen-free facility at Yale University.
Yeast display screening. To prepare RNA for library construction, we harvested the salivary glands from about 300 A. aegypti mosquitoes that had fed once on mice. RNA was purified with the RNeasy Mini kit (QIAGEN) and the purity of the collected RNA was validated by gel electrophoresis to confirm the presence of 18S and 28S ribosomal RNA. Complementary DNA was synthesized by a modified SMART cDNA synthesis kit according to the protocols by Bio S&T Inc. After double-stranded cDNAs were generated by primer extension and cDNA normalization, the cDNAs were directionally cloned into the yeast expression vector pYD1 (Invitrogen) to generate a salivary gland expression library (Invitrogen). The digestion of plasmids purified from ten clones of the pYD1-salivary gland library showed an average insert size of 1.2 kb and all of the clones contained inserts. The total number of primary clones was over one million. Plasmid DNA was purified from the library using a QIAGEN Plasmid Midi kit. Growth of transformed yeast cells and induction of recombinant protein production was performed as previously described 14, 31 . Briefly, fresh Saccharomyces cerevisiae EBY100 cells (Invitrogen) were electroporated with 2 µg plasmid DNA and subsequently grown overnight in SDCAA medium (2% dextrose, 0.67% yeast nitrogen base, 0.5% bacto amino acids, 30 mM NaHPO 4 and 62 mM NaH 2 PO 4 ) at 30°C with shaking at 200 r.p.m.
The induction of surface protein expression was performed as described previously 14, 31 . In brief, transformed yeast cells were grown for 24 h at 30 °C in SGCAA medium (2% galactose, 0.67% yeast nitrogen base, 0.5% bacto amino acids, 30 mM NaHPO 4 and 62 mM NaH 2 PO 4 ). After induction with galactose, selection was performed by MACS separation (Miltenyi Biotec). The induced yeast cells were incubated with purified IgG derived from mice repeatedly bitten by A. aegypti. For MACS separation, an LS column (Mitenyi Biotec, cat. no.130-042-401) was placed onto the magnet and stand assembly. After washing the column, the induced yeast cells were applied to the column. After passing through the column, the bound yeast cells were eluted by removing the column from the magnet and adding SDCAA medium to the column. The eluted yeast cells then were propagated for further rounds of sorting. After four rounds of magnetic sorting, the plasmids were recovered using a Zymoprep II yeast Plasmid Miniprep kit (Zymo Research), transformed into Escherichia coli DH5α-competent cells (Invitrogen) and sequenced.
Purification of recombinant proteins and antiserum preparation. AgBR1
(AAEL001965), SP (AAEL003600) and D7Bclu (AAEL006417) were cloned inframe into the pMT-Bip-V5-His tag vector (Invitrogen) and recombinant proteins expressed and purified using the Drosophila Expression System (Invitrogen) as described previously 14 . AgBR1, SP and D7Bclu were purified from the supernatant by TALON metal affinity resin (Clontech) and eluted with 150 mM imidazole. The eluted samples were filtered through a 0.22-µm filter and concentrated with a 10-kDa concentrator (Sigma-Aldrich) by centrifugation at 4 °C, and washed and dialysed against PBS. Recombinant protein purities were assessed by SDS-PAGE and quantified using the BCA Protein Estimation kit (Thermo Scientific). The PCR primer sequences for cloning are listed in Supplementary Table 6 .
To generate rabbit sera against recombinant proteins, rabbits were immunized subcutaneously with 80-150 µg recombinant proteins in complete Freund's adjuvant and boosted twice at two-week intervals with 80-150 µg recombinant proteins in incomplete Freund's adjuvant. The rabbits were euthanized and sera were obtained by cardiac puncture two weeks after the final boost. The reactivity to recombinant proteins was examined by immunoblotting and ELISA.
ELISA. Recombinant AgBR1, SP, D7Bclu, OVA or salivary-gland extracts in PBS (0.1 µg per 50 µl per well) were coated on 96-well plates overnight at 4 °C. After being blocked with 2% non-fat milk for 1 h at room temperature, the plates were incubated for 1 h at room temperature with serum samples serially diluted in PBS. After three washes with PBS containing 0.05% Tween-20 (PBS-T; Sigma), the plates were incubated with horseradish peroxidase-conjugated secondary antibodies. Enzyme activity was detected by incubation with 100 μl 3,3′,5,5′-tetramethylbenzidine solution (KPL) for 15 min at room temperature in the dark. The reaction was stopped by the addition of 1 M H 2 SO 4 . The optical density (OD) at 450 nm was measured with a microplate reader.
Immunoblot. Recombinant proteins, BSA or salivary-gland extracts were separated by SDS-PAGE using 4-20% Mini-Protean TGX gels (Bio-Rad) at 200 V for 25 min. Proteins were transferred onto a PVDF membrane for 60 min at 4 V. The blots were blocked in 1% non-fat milk in water for 60 min. Primary antibodies were diluted in 0.05% PBS-T and incubated with the blots for 1 h at room temperature or 4 °C overnight. Horseradish peroxidase-conjugated secondary antibodies were diluted in PBS-T and incubated for 1 h at room temperature. After washing with PBS-T, the immunoblots were imaged with a LI-COR Odyssey imaging system.
Splenocyte stimulation with recombinant AgBR1. Splenocytes were isolated from C57BL/6 mice. Briefly, the spleens were minced in RPMI 1640 medium (Sigma-Aldrich) and gently forced through a 70 µm cell-strainer nylon mesh using a sterile syringe plunger and centrifuged at 400g for 5 min. After a single wash with cold PBS, spleen cells were incubated in 2 ml 0.83% NH 4 Cl for 5 min, placed in 20 ml PBS, centrifuged at 400g for 5 min and then resuspended in RPMI 1640. The total number of cells was calculated using a haemocytometer. Isolated splenocytes were stimulated with 5 μg ml −1 recombinant AgBR1 or BSA and cultured with serum-free RPMI medium for 6 and 24 h. Total RNA was extracted using a RNeasy Mini kit (QIAGEN) according to the instructions. The cDNA was generated with an iScript cDNA synthesis kit (Bio-Rad) according to manufacturer's protocol. Gene expression was examined by qRT-PCR using IQ SYBR Green Supermix. The target gene messenger RNA levels were normalized to mouse β actin RNA levels according to 2 −ΔΔCt calculations. The qRT-PCR primer sequences are listed in Supplementary Table 6 .
Co-inoculation of Zika virus with AgBR1. AG129 mice were inoculated via subcutaneous (footpad) injection with 3 plaque-forming units (PFU) of Zika virus along with 10 µg AgBR1 (40 µl total volume). Survival was monitored every day postinfection. Mice exhibiting neurological disease, such as paralysis, or a loss of >20% of body weight were euthanized. The weight loss is very rapid and usually begins three days before death, coinciding with neurological symptoms. Total RNA from murine blood was extracted in TRIzol reagent and qRT-PCR was performed to examine Zika virus levels as previously described 32 .
Passive or active immunization studies. Zika virus injection was performed as previously described 30 . Briefly, Zika-virus-filled needles were carefully inserted into the thorax of each mosquito and 69 nl virus (100 PFU) was injected using a Nanoject II Auto-Nanoliter Injector (Drummond). Infected mosquitoes were placed back in paper cups with mesh lids and maintained in triple containment for ten days in a warm chamber. The mosquitoes were knocked down on ice and their salivary glands were dissected to examine the virus levels after mosquito feeding. The RNA from salivary glands was purified with the RNeasy Mini kit (QIAGEN) and cDNA was generated with an iScript cDNA synthesis kit (Bio-Rad) according to the manufacturer's protocol. Gene expression was examined by qRT-PCR using IQ SYBR Green Supermix. Viral RNA levels were normalized to mosquito Rp49 RNA levels according to 2 −ΔΔCt calculations.
For passive rabbit-antiserum transfer experiments, mice were injected intraperitoneally with antiserum (150 µl per animal) against specific mosquito proteins or naive rabbit serum one day before challenge. On the same day, two infected mosquitoes were randomly aliquoted into individual cups with mesh covers. The mice were anaesthetized with ketamine-xylazine and fed on by two Zika-virus-infected mosquitoes on the following day. For active immunization, mice were immunized subcutaneously with 10 µg AgBR1 or ovalbumin in complete Freund's adjuvant and boosted twice every two weeks with the same amount of AgBR1 or ovalbumin in incomplete Freund's adjuvant. Two weeks after the final immunization, the mice were anaesthetized with ketamine-xylazine and fed on by two Zika-virus-infected mosquitoes. The blood of the mosquito-bitten mice was collected at days 1, 3, 5, 7 and 9 postinfection. Survival was monitored daily. Mice exhibiting a weight loss of >20% of initial body weight or neurological disease were euthanized. Viraemia levels were examined at days 1, 3, 5, 7 and 9 postinfection as described above.
Needle inoculation of Zika virus after passive immunization.
Mice were injected intraperitoneally with control serum or AgBR1 antiserum one day before challenge. On the following day, the mice were inoculated via subcutaneous footpad injection with 0.3 PFU Zika virus. Survival was monitored every day postinfection. Mice exhibiting weight loss of >20% of initial body weight or neurologic disease were euthanized. Viraemia levels were examined at days 1, 3, 5, 7 and 9 postinfection as described above.
Gene silencing. RNA interference of genes expressed in the mosquito SGs was performed as previously described. Double-stranded (ds) RNA targeting either a 400 bp region of the AgBR1 gene or an irrelevant green fluorescent protein gene were transcribed using gene-specific primers designed with a T7 promoter and the MEGAScript RNAi kit (Thermo Fisher Scientific, Ambion). The primers for generating dsRNA are listed in Supplementary Table 6 . To silence the AgBR1 gene, adult female A. aegypti mosquitoes were kept on ice and then transferred to a cold tray to receive a dsRNA injection. A Nanoject II Auto-Nanoliter Injector (Drummond) was used to microinject 200 ng dsRNA in PBS into the thorax of each mosquito. At day 3 following dsRNA injection, the mosquitoes were knockeddown on ice and injected with Zika virus described above. At day 10 following virus injection, the salivary glands were dissected to examine the AgBR1 expression levels by qRT-PCR and AgBR1 protein production by immunoblotting.
Analysis of local immune responses after bites by Zika-virus-infected mosquitoes or intradermal injection. For the analysis of the local immune responses after bites by Zika-virus-infected mosquitoes, Zika-virus-infected A.
aegypti mosquitoes were allowed to feed on the left ear of AG129 mice.
For the analysis of the local immune responses after intradermal injection, AgBR1 was intradermally injected into the left ear of AG129 mice. Briefly, the ear of an individual mouse was gently immobilized over a 14-ml-falcon tube covered with double-sided tape. The dorsal ear was intradermally injected with 500 nl of 0.5 µg µl −1 AgBR1 using a glass micropipette with a 80 µm-diameter bevelled opening made as described elsewhere 33 and a Nanoject II Auto-Nanoliter Injector (Drummond).
The mice were euthanized one day later and the locations of the mosquito bites and intradermal injections, and naive skins were punched using a disposable biopsy punch. Total RNA was extracted using a RNeasy Fibrous Tissue Mini kit (QIAGEN) according to the manufacturer's instructions.
For qRT-PCR, the cDNA generation and analysis of gene expression was conducted as described above. Gene expression was queried using IQ SYBR Green Supermix. Target gene mRNA levels were normalized to mouse β actin RNA levels according to 2 −ΔΔCt calculations. The qRT-PCR primer sequences are listed in Supplementary Table 6 .
For RNA-seq library preparation and sequencing, barcoded libraries were generated by standard Truseq mRNA library protocol (Illumina) and sequenced with a 2 × 75 bp paired-end protocol on the HiSeq 4000 sequencing system (Illumina).
All of the analyses of RNA-seq data were performed using Partek Flow (v7.0). RNA-seq data were trimmed and mapped to a mm10 genome reference using STAR (2.5.0e). The aligned reads were quantified to ENSEMBL transcripts release 91 using the Partek E/M algorithm and the subsequent steps were performed on gene-level annotation followed by total count normalization. The gene-level data were normalized by dividing the gene counts by the total number of reads followed by addition of a small offset (0.001). Differential expression was assessed by fitting the Partek's log-normal model with shrinkage (comparable in performance to limma-trend). Genes with a geometric mean below the value of 1.0 were filtered out from the analysis. Hierarchal clustering was performed on the genes that were differentially expressed across the conditions (P < 0.05, fold change > 1.5 for each comparison). GSEA was performed on normalized gene expression counts of RNA-seq data as described previously 34 . Gene sets with an estimated false discovery rate of <0.05 were considered significant according to the GSEA guidelines.
Histopathology. Ear skins of the bite site and non-bite site on the contralateral ear were harvested by punch biopsy, fixed in 4% paraformaldehyde/PBS, paraffin embedded, and processed for haematoxylin and eosin staining. The histological findings were scored for the severity and character of the inflammatory response using a blinded grading scale that was previously described 35 , with minor modifications. Responses were graded as follows: 0, no response; 1, minimal response; 2, mild response; 3, moderate response and 4, marked response. The responses were evaluated and graded on the histological sites with the most prominent responses in each specimen. The total histology score was calculated as the sum of scores, including inflammation, neutrophils, mononuclear cells and oedema. The slides were blinded, randomized and reread to determine the histology score by the same dermatopathologist throughout all studies.
Imaging mass cytometry. Imaging mass cytometry was performed on slides dewaxed in xylene for 20 min according to previously described studies 36 . After hydration in sequential concentrations of ethanol (100%, 95%, 80% and 70%) for 5 min, the slides were incubated with antigen retrieval solution at 90-95 °C for 20 min. The slides were then cooled to room temperature and washed with ddH 2 O and PBS (lacking Ca ++ or Mg ++ ) for 5 min. After blocking with 3% BSA in PBS for 45 min, the slides were labelled overnight at 4 °C with metal-conjugated antibodies against CD3 (170Er, polyclonal, C-terminal), CD11b (149Sm, EPR1344), MHCII (174Yb, M5/114.15.2) and Ly6G (141Pr, 1A8) diluted in PBS with 0.5% BSA. After a wash with 0.1% Triton-X in PBS followed by PBS, the slides were labelled with intercalator-Ir (1:2,000 dilution) in PBS (lacking Ca ++ or Mg ++ ) for 30 min at room temperature. The slides were dried after another wash with ddH 2 O for 5 min. Tissues were laser ablated using a 200 Hz Hyperion Imaging System (Fluidigm Corp.) and the aerosol containing the ion cloud was directly transported to a Helios mass cytometer (Fluidigm). The images of labelled slides were obtained using the MCD viewer 1.0 (https://www.fluidigm.com/software).
Analysis of immune cells in mice following Zika-virus-infected mosquito bites or intradermal injection.
For the analysis of the immune cells following Zikavirus-infected mosquito bites, Zika-virus-infected A. aegypti mosquitoes were allowed to feed on the ears of AG129 mice.
For the analysis of the immune cells following AgBR1 injection, AG129 mice were intradermally injected with AgBR1 in the ear as described above.
After 24 h, the mice were sacrificed and both the bitten or injected and naive ears were cut off at the base and split into dorsal and ventral halves. The ears were incubated for 1.5 h in 2 mg ml −1 Dispase II (Sigma) in DMEM media with 10% FBS and then cut into small pieces. The small pieces were then digested for 1.5 h in 5 mg ml −1 collagenase (Gibco) in media. The digested samples were then individually passed through 70-μM filters to obtain single-cell suspensions.
After washing once with PBS containing 2% FBS (FACS buffer), cells were stained using the LIVE/DEAD Fixable Violet Dead Cell Stain kit (Thermo Fisher), incubated with fluorochrome-conjugated monoclonal antibodies against CD45 (PerCP; BD Pharmingen; clone 30-F11), MHCII (APC-Cy7; Biolegend; clone M4/114.15.2), CD11b (PE; Biolegend; clone M1/70), CD11c (PE-Cy7; BD Pharmingen; clone HL3) and Ly6G (FITC; Tonbo; clone RB6-8C5) for 30 min at room temperature and washed twice with FACS buffer. The samples were run on a BD LSRII flow cytometer and analysed using FlowJo software.
Statistical analysis. GraphPad Prism software was used to analyse all of the data. Animals were randomly allocated into different groups. No statistical methods 1 nature research | reporting summary
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